12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eravacycline: Phase II data

Tetraphase reported data from the microbiologically evaluable population (n=109) in a double-blind, international Phase II trial showing that IV eravacycline for up to 14 days met the primary endpoint of clinical cure rate at the TOC visit 10-14 days after the end of treatment vs. ertapenem. Specifically, once-daily 1.5 mg/kg IV eravacycline led to a clinical cure rate of 92.9% and twice-daily 1...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >